HRD status is a biomarker in tumors with high levels of DNA damage, such as ovarian, breast, prostate, and pancreatic cancers. It describes when cells are unable to effectively repair double-stranded DNA breaks and may lead to genomic instability and, eventually, tumor formation.

The research use only TruSight Oncology 500 HRD test is a next-generation sequencing (NGS)-based assay that combines Illumina's NGS technology with Myriad Genetics's HRD technology to detect genomic instability and analyze more than 500 genes simultaneously.

The research test is expected to ship globally (excluding the U.S. and Japan) in August.

Illumina highlights new product, presentations at AGBT meeting
Illumina is debuting a new product and sharing presentations at the Advances in Genome Biology and Technology (AGBT) General Meeting taking place June...

NanoString improves Illumina’s sequencing systems via data workflow
NanoString Technologies has released a cloud-based workflow to enable simplified data analysis for researchers using Illumina’s NextSeq 1000 and NextSeq...

Illumina and Deerfield Management enter into drug development partnership
Illumina and Deerfield Management have entered into a partnership to accelerate drug discovery and development using genetic technologies and artificial...

Biocytogen partners with Merck to evaluate novel antibodies
Biocytogen Pharmaceuticals has entered into an evaluation and option agreement with Merck KGaA to evaluate Biocytogen’s antibodies. The agreement will...

Artiva announces new NK agreement with Merck
Artiva Biotherapeutics entered into an agreement with Merck to evaluate the therapeutic potential of Artiva's clinical-grade AB-101 natural killer (NK)...

Merck receives positive opinion from EMA for Keytruda
Merck announced that it received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use recommending...